window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : January 20, 2026

  • News
  • About Us
Contact Us

Central Nervous System

  • Biotech,Central Nervous System,Healthcare leadership,Movers & Shakers,Neurosciences

    AstronauTx appoints Adam Rosenberg as Chair of the Board

    AstronauTx has appointed Adam Rosenberg as chair of the board, [...]

    January 14, 2026
  • Central Nervous System,Child & Adolescnt Health,Drug Development,Pharmaceuticals and therapeutics

    Neuraxpharm expands ADHD treatment options in Europe with Tuzulby and Paxneury launches

    Neuraxpharm has launched two new treatments for attention deficit hyperactivity [...]

    January 12, 2026
  • Biotech,Central Nervous System,Clinical Development,European biotech,Regulatory Affairs

    Single-cell analysis highlights molecular subgroups in endometriosis that could inform clinical trials

    Endometriosis is typically treated as a single condition, yet patients [...]

    January 7, 2026
  • Biotech,Central Nervous System,Clinical Development,European biotech,Regulatory Affairs

    Newron expands evenamide IP protection with new EU composition of matter patent

    Newron has expanded the intellectual property protection for its lead [...]

    January 6, 2026
  • Central Nervous System,Clinical Trials,Pharmaceuticals and therapeutics,Research & Development

    CNS Pharmaceuticals announces primary analysis of Berubicin in second line treatment of glioblastoma multiforme

    CNS Pharmaceuticals has reported the primary analysis of its clinical [...]

    November 25, 2025
  • Central Nervous System,Neurosciences,Pharmaceuticals and therapeutics,Research & Development

    Porosome reconstitution therapy reverses Alzheimer’s pathology in human brain organoids

    Porosome Therapeutics has reported preclinical results showing that restoring porosome [...]

    November 18, 2025
  • Biotech,Central Nervous System,Clinical Development,Neurosciences,Partnerships & Funding,Research & Development

    Modulight Biotherapeutics raises $12 million seed funding for optogenetic therapy development

    Modulight Biotherapeutics has raised $12.2 million in a Seed funding [...]

    November 13, 2025
  • Central Nervous System,Clinical studies,Digital Health,Mental health,Neurosciences

    At-home brain stimulation therapy helps prevent depression relapse, study finds

    A major international study has found that remotely supervised, at-home [...]

    November 12, 2025
  • Central Nervous System,Drug Development,Pharmaceuticals and therapeutics,Rare Diseases

    FDA authorises Emalex Biosciences’ Expanded Access Program for Tourette syndrome drug

    Emalex Biosciences has received FDA authorisation for an Expanded Access [...]

    October 8, 2025
  • Central Nervous System,Clinical Trials,Drug Development,Pharmaceuticals and therapeutics

    Celon Pharma receives FDA clearance for Phase 3 trial of CPL’36 in schizophrenia

    Celon Pharma S.A. has received FDA clearance to advance its [...]

    October 8, 2025
12Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Cereno Scientific publishes first peer-reviewed data on HDAC inhibitor CS014 showing antithrombotic effects without bleeding risk
    Categories: Biotech, Clinical Development, Drug Development, European biotech, Hematology, Research & Development, Respiratory
  • SPT Labtech adds automated Twist Bioscience NGS library preparation workflows to firefly platform
    Categories: Data Management, Genomics and sequencing, Research & Development, Technology and platforms
  • Almirall to launch phase 3 LumiNE study of lebrikizumab in nummular eczema
    Categories: Clinical Trials, Dermatology, Drug Development, European biotech, Pharmaceuticals and therapeutics
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top